Global Inhalation Anesthesia

Inhalation Anesthesia Comprehensive Study by Type (Sevoflurane, Isoflurane, Desflurane, Enflurane, Halothane, Xenon, Nitrous Oxide), Application (Induction, Maintenance), Phase (Pulmonary Phase, Circularly Phase, Tissue Phase), End User (Hospitals, Ambulatory Surgical Centers, Other) Players and Region - Global Market Outlook to 2030

Inhalation Anesthesia Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 4.13%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Inhalation Anesthesia
Inhalation Anesthesia is used for the induction and maintenance of general anesthesia in the operating room. Anesthesia is a chemical compound with the anesthetic properties and is safe for longer surgical procedures. In the inhalation anesthesia technique, the anesthesia is passed through lungs induces unconsciousness during surgery. Inhalational anesthesia used for sedation, induction, and maintenance of general anesthesia. The rising number of orthopedic procedures and emergency cases has boosted the growth of global inhalation anesthesia market

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Million)
CAGR4.13%


The demand for Inflight Internet Services is increasing due to the rising of Inflight Entertainment by each passing day. Businesses in this sector face global competition from market leaders who control a large share of the market. The Leading Players are engaged in organic and non-organic strategic global expansion to maintain their Market Position. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Inhalation Anesthesia market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck KGaA (Germany), Halocarbon Products Corporation (United States), Hikima Pharmaceuticals PLC (London), Lunan Pharmaceutical Group Co. Ltd. (China), Piramal Enterprises Limited (India), Jiangsu Hengrui Medicine Co. Ltd. (China), Fresenius Kabi AG (Germany), AbbVie Inc. (United States), Baxter International Inc. (United States), Novartis AG (Switzerland) and Troikaa Pharmaceuticals Ltd (India) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Inhalation Anesthesia market by Type (Sevoflurane, Isoflurane, Desflurane, Enflurane, Halothane, Xenon and Nitrous Oxide), Application (Induction and Maintenance) and Region.



On the basis of geography, the market of Inhalation Anesthesia has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. If we see Market by Phase, the sub-segment i.e. Pulmonary Phase will boost the Inhalation Anesthesia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Inhalation Anesthesia market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Adoption of Short Duration and Predictable Nature of Inhalation Anesthesia

Market Growth Drivers:
Growing Demand for Surgical Procedures, Aging Population Suffering Various Chronic Diseases and Rise in Healthcare Reforms

Challenges:
Side Effects Associated With Anesthetics

Restraints:
Availability of Generic Products

Opportunities:
Increasing Number of Emergency Cases and Accidents, Rapidly Growing Number of Hospitals in Emerging Countries and Developing R&D Sector

Market Leaders and their expansionary development strategies
In 2020, Piramal Critical Care (PCC) has announced a strategic agreement with Medivant Healthcare, a US-based pharmaceutical outsourcing facility, to help address a severe injectable drug shortage in hospitals across the country.
In 2021, International pharmaceutical business has launched Succinylcholine Chloride Injection USP 20mg/mL in the United States. In addition to general anesthesia, it is used for tracheal intubation and to aid in tracheal intubation. Provide skeletal muscle relaxation during surgery or mechanical ventilation.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Inhalation Anesthesia Manufacturer, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Sevoflurane
  • Isoflurane
  • Desflurane
  • Enflurane
  • Halothane
  • Xenon
  • Nitrous Oxide
By Application
  • Induction
  • Maintenance
By Phase
  • Pulmonary Phase
  • Circularly Phase
  • Tissue Phase

By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Demand for Surgical Procedures
      • 3.2.2. Aging Population Suffering Various Chronic Diseases
      • 3.2.3. Rise in Healthcare Reforms
    • 3.3. Market Challenges
      • 3.3.1. Side Effects Associated With Anesthetics
    • 3.4. Market Trends
      • 3.4.1. Adoption of Short Duration and Predictable Nature of Inhalation Anesthesia
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Inhalation Anesthesia, by Type, Application, Phase, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Inhalation Anesthesia (Value)
      • 5.2.1. Global Inhalation Anesthesia by: Type (Value)
        • 5.2.1.1. Sevoflurane
        • 5.2.1.2. Isoflurane
        • 5.2.1.3. Desflurane
        • 5.2.1.4. Enflurane
        • 5.2.1.5. Halothane
        • 5.2.1.6. Xenon
        • 5.2.1.7. Nitrous Oxide
      • 5.2.2. Global Inhalation Anesthesia by: Application (Value)
        • 5.2.2.1. Induction
        • 5.2.2.2. Maintenance
      • 5.2.3. Global Inhalation Anesthesia by: Phase (Value)
        • 5.2.3.1. Pulmonary Phase
        • 5.2.3.2. Circularly Phase
        • 5.2.3.3. Tissue Phase
      • 5.2.4. Global Inhalation Anesthesia by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Ambulatory Surgical Centers
        • 5.2.4.3. Other
      • 5.2.5. Global Inhalation Anesthesia Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Inhalation Anesthesia: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck KGaA (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Halocarbon Products Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Hikima Pharmaceuticals PLC (London)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Lunan Pharmaceutical Group Co. Ltd. (China)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Piramal Enterprises Limited (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Jiangsu Hengrui Medicine Co. Ltd. (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Fresenius Kabi AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AbbVie Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Baxter International Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Troikaa Pharmaceuticals Ltd (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Inhalation Anesthesia Sale, by Type, Application, Phase, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Inhalation Anesthesia (Value)
      • 7.2.1. Global Inhalation Anesthesia by: Type (Value)
        • 7.2.1.1. Sevoflurane
        • 7.2.1.2. Isoflurane
        • 7.2.1.3. Desflurane
        • 7.2.1.4. Enflurane
        • 7.2.1.5. Halothane
        • 7.2.1.6. Xenon
        • 7.2.1.7. Nitrous Oxide
      • 7.2.2. Global Inhalation Anesthesia by: Application (Value)
        • 7.2.2.1. Induction
        • 7.2.2.2. Maintenance
      • 7.2.3. Global Inhalation Anesthesia by: Phase (Value)
        • 7.2.3.1. Pulmonary Phase
        • 7.2.3.2. Circularly Phase
        • 7.2.3.3. Tissue Phase
      • 7.2.4. Global Inhalation Anesthesia by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Ambulatory Surgical Centers
        • 7.2.4.3. Other
      • 7.2.5. Global Inhalation Anesthesia Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Inhalation Anesthesia: by Type(USD Million)
  • Table 2. Inhalation Anesthesia Sevoflurane , by Region USD Million (2018-2023)
  • Table 3. Inhalation Anesthesia Isoflurane , by Region USD Million (2018-2023)
  • Table 4. Inhalation Anesthesia Desflurane , by Region USD Million (2018-2023)
  • Table 5. Inhalation Anesthesia Enflurane , by Region USD Million (2018-2023)
  • Table 6. Inhalation Anesthesia Halothane , by Region USD Million (2018-2023)
  • Table 7. Inhalation Anesthesia Xenon , by Region USD Million (2018-2023)
  • Table 8. Inhalation Anesthesia Nitrous Oxide , by Region USD Million (2018-2023)
  • Table 9. Inhalation Anesthesia: by Application(USD Million)
  • Table 10. Inhalation Anesthesia Induction , by Region USD Million (2018-2023)
  • Table 11. Inhalation Anesthesia Maintenance , by Region USD Million (2018-2023)
  • Table 12. Inhalation Anesthesia: by Phase(USD Million)
  • Table 13. Inhalation Anesthesia Pulmonary Phase , by Region USD Million (2018-2023)
  • Table 14. Inhalation Anesthesia Circularly Phase , by Region USD Million (2018-2023)
  • Table 15. Inhalation Anesthesia Tissue Phase , by Region USD Million (2018-2023)
  • Table 16. Inhalation Anesthesia: by End User(USD Million)
  • Table 17. Inhalation Anesthesia Hospitals , by Region USD Million (2018-2023)
  • Table 18. Inhalation Anesthesia Ambulatory Surgical Centers , by Region USD Million (2018-2023)
  • Table 19. Inhalation Anesthesia Other , by Region USD Million (2018-2023)
  • Table 20. South America Inhalation Anesthesia, by Country USD Million (2018-2023)
  • Table 21. South America Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 22. South America Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 23. South America Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 24. South America Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 25. Brazil Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 26. Brazil Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 27. Brazil Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 28. Brazil Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 29. Argentina Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 30. Argentina Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 31. Argentina Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 32. Argentina Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 33. Rest of South America Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 34. Rest of South America Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 35. Rest of South America Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 36. Rest of South America Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 37. Asia Pacific Inhalation Anesthesia, by Country USD Million (2018-2023)
  • Table 38. Asia Pacific Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 39. Asia Pacific Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 40. Asia Pacific Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 41. Asia Pacific Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 42. China Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 43. China Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 44. China Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 45. China Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 46. Japan Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 47. Japan Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 48. Japan Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 49. Japan Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 50. India Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 51. India Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 52. India Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 53. India Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 54. South Korea Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 55. South Korea Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 56. South Korea Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 57. South Korea Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 58. Taiwan Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 59. Taiwan Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 60. Taiwan Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 61. Taiwan Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 62. Australia Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 63. Australia Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 64. Australia Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 65. Australia Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 70. Europe Inhalation Anesthesia, by Country USD Million (2018-2023)
  • Table 71. Europe Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 72. Europe Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 73. Europe Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 74. Europe Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 75. Germany Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 76. Germany Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 77. Germany Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 78. Germany Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 79. France Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 80. France Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 81. France Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 82. France Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 83. Italy Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 84. Italy Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 85. Italy Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 86. Italy Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 87. United Kingdom Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 88. United Kingdom Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 89. United Kingdom Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 90. United Kingdom Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 91. Netherlands Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 92. Netherlands Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 93. Netherlands Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 94. Netherlands Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 95. Rest of Europe Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 96. Rest of Europe Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 97. Rest of Europe Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 98. Rest of Europe Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 99. MEA Inhalation Anesthesia, by Country USD Million (2018-2023)
  • Table 100. MEA Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 101. MEA Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 102. MEA Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 103. MEA Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 104. Middle East Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 105. Middle East Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 106. Middle East Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 107. Middle East Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 108. Africa Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 109. Africa Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 110. Africa Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 111. Africa Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 112. North America Inhalation Anesthesia, by Country USD Million (2018-2023)
  • Table 113. North America Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 114. North America Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 115. North America Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 116. North America Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 117. United States Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 118. United States Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 119. United States Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 120. United States Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 121. Canada Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 122. Canada Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 123. Canada Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 124. Canada Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 125. Mexico Inhalation Anesthesia, by Type USD Million (2018-2023)
  • Table 126. Mexico Inhalation Anesthesia, by Application USD Million (2018-2023)
  • Table 127. Mexico Inhalation Anesthesia, by Phase USD Million (2018-2023)
  • Table 128. Mexico Inhalation Anesthesia, by End User USD Million (2018-2023)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Inhalation Anesthesia: by Type(USD Million)
  • Table 141. Inhalation Anesthesia Sevoflurane , by Region USD Million (2025-2030)
  • Table 142. Inhalation Anesthesia Isoflurane , by Region USD Million (2025-2030)
  • Table 143. Inhalation Anesthesia Desflurane , by Region USD Million (2025-2030)
  • Table 144. Inhalation Anesthesia Enflurane , by Region USD Million (2025-2030)
  • Table 145. Inhalation Anesthesia Halothane , by Region USD Million (2025-2030)
  • Table 146. Inhalation Anesthesia Xenon , by Region USD Million (2025-2030)
  • Table 147. Inhalation Anesthesia Nitrous Oxide , by Region USD Million (2025-2030)
  • Table 148. Inhalation Anesthesia: by Application(USD Million)
  • Table 149. Inhalation Anesthesia Induction , by Region USD Million (2025-2030)
  • Table 150. Inhalation Anesthesia Maintenance , by Region USD Million (2025-2030)
  • Table 151. Inhalation Anesthesia: by Phase(USD Million)
  • Table 152. Inhalation Anesthesia Pulmonary Phase , by Region USD Million (2025-2030)
  • Table 153. Inhalation Anesthesia Circularly Phase , by Region USD Million (2025-2030)
  • Table 154. Inhalation Anesthesia Tissue Phase , by Region USD Million (2025-2030)
  • Table 155. Inhalation Anesthesia: by End User(USD Million)
  • Table 156. Inhalation Anesthesia Hospitals , by Region USD Million (2025-2030)
  • Table 157. Inhalation Anesthesia Ambulatory Surgical Centers , by Region USD Million (2025-2030)
  • Table 158. Inhalation Anesthesia Other , by Region USD Million (2025-2030)
  • Table 159. South America Inhalation Anesthesia, by Country USD Million (2025-2030)
  • Table 160. South America Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 161. South America Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 162. South America Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 163. South America Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 164. Brazil Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 165. Brazil Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 166. Brazil Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 167. Brazil Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 168. Argentina Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 169. Argentina Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 170. Argentina Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 171. Argentina Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 172. Rest of South America Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 173. Rest of South America Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 174. Rest of South America Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 175. Rest of South America Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 176. Asia Pacific Inhalation Anesthesia, by Country USD Million (2025-2030)
  • Table 177. Asia Pacific Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 178. Asia Pacific Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 179. Asia Pacific Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 180. Asia Pacific Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 181. China Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 182. China Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 183. China Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 184. China Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 185. Japan Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 186. Japan Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 187. Japan Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 188. Japan Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 189. India Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 190. India Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 191. India Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 192. India Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 193. South Korea Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 194. South Korea Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 195. South Korea Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 196. South Korea Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 197. Taiwan Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 198. Taiwan Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 199. Taiwan Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 200. Taiwan Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 201. Australia Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 202. Australia Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 203. Australia Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 204. Australia Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 206. Rest of Asia-Pacific Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 207. Rest of Asia-Pacific Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 208. Rest of Asia-Pacific Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 209. Europe Inhalation Anesthesia, by Country USD Million (2025-2030)
  • Table 210. Europe Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 211. Europe Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 212. Europe Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 213. Europe Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 214. Germany Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 215. Germany Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 216. Germany Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 217. Germany Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 218. France Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 219. France Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 220. France Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 221. France Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 222. Italy Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 223. Italy Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 224. Italy Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 225. Italy Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 226. United Kingdom Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 227. United Kingdom Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 228. United Kingdom Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 229. United Kingdom Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 230. Netherlands Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 231. Netherlands Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 232. Netherlands Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 233. Netherlands Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 234. Rest of Europe Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 235. Rest of Europe Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 236. Rest of Europe Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 237. Rest of Europe Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 238. MEA Inhalation Anesthesia, by Country USD Million (2025-2030)
  • Table 239. MEA Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 240. MEA Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 241. MEA Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 242. MEA Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 243. Middle East Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 244. Middle East Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 245. Middle East Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 246. Middle East Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 247. Africa Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 248. Africa Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 249. Africa Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 250. Africa Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 251. North America Inhalation Anesthesia, by Country USD Million (2025-2030)
  • Table 252. North America Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 253. North America Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 254. North America Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 255. North America Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 256. United States Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 257. United States Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 258. United States Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 259. United States Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 260. Canada Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 261. Canada Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 262. Canada Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 263. Canada Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 264. Mexico Inhalation Anesthesia, by Type USD Million (2025-2030)
  • Table 265. Mexico Inhalation Anesthesia, by Application USD Million (2025-2030)
  • Table 266. Mexico Inhalation Anesthesia, by Phase USD Million (2025-2030)
  • Table 267. Mexico Inhalation Anesthesia, by End User USD Million (2025-2030)
  • Table 268. Research Programs/Design for This Report
  • Table 269. Key Data Information from Secondary Sources
  • Table 270. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Inhalation Anesthesia: by Type USD Million (2018-2023)
  • Figure 5. Global Inhalation Anesthesia: by Application USD Million (2018-2023)
  • Figure 6. Global Inhalation Anesthesia: by Phase USD Million (2018-2023)
  • Figure 7. Global Inhalation Anesthesia: by End User USD Million (2018-2023)
  • Figure 8. South America Inhalation Anesthesia Share (%), by Country
  • Figure 9. Asia Pacific Inhalation Anesthesia Share (%), by Country
  • Figure 10. Europe Inhalation Anesthesia Share (%), by Country
  • Figure 11. MEA Inhalation Anesthesia Share (%), by Country
  • Figure 12. North America Inhalation Anesthesia Share (%), by Country
  • Figure 13. Global Inhalation Anesthesia share by Players 2023 (%)
  • Figure 14. Global Inhalation Anesthesia share by Players (Top 3) 2023(%)
  • Figure 15. Global Inhalation Anesthesia share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 19. Halocarbon Products Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 20. Halocarbon Products Corporation (United States) Revenue: by Geography 2023
  • Figure 21. Hikima Pharmaceuticals PLC (London) Revenue, Net Income and Gross profit
  • Figure 22. Hikima Pharmaceuticals PLC (London) Revenue: by Geography 2023
  • Figure 23. Lunan Pharmaceutical Group Co. Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 24. Lunan Pharmaceutical Group Co. Ltd. (China) Revenue: by Geography 2023
  • Figure 25. Piramal Enterprises Limited (India) Revenue, Net Income and Gross profit
  • Figure 26. Piramal Enterprises Limited (India) Revenue: by Geography 2023
  • Figure 27. Jiangsu Hengrui Medicine Co. Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 28. Jiangsu Hengrui Medicine Co. Ltd. (China) Revenue: by Geography 2023
  • Figure 29. Fresenius Kabi AG (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Fresenius Kabi AG (Germany) Revenue: by Geography 2023
  • Figure 31. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Baxter International Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 37. Troikaa Pharmaceuticals Ltd (India) Revenue, Net Income and Gross profit
  • Figure 38. Troikaa Pharmaceuticals Ltd (India) Revenue: by Geography 2023
  • Figure 39. Global Inhalation Anesthesia: by Type USD Million (2025-2030)
  • Figure 40. Global Inhalation Anesthesia: by Application USD Million (2025-2030)
  • Figure 41. Global Inhalation Anesthesia: by Phase USD Million (2025-2030)
  • Figure 42. Global Inhalation Anesthesia: by End User USD Million (2025-2030)
  • Figure 43. South America Inhalation Anesthesia Share (%), by Country
  • Figure 44. Asia Pacific Inhalation Anesthesia Share (%), by Country
  • Figure 45. Europe Inhalation Anesthesia Share (%), by Country
  • Figure 46. MEA Inhalation Anesthesia Share (%), by Country
  • Figure 47. North America Inhalation Anesthesia Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck KGaA (Germany)
  • Halocarbon Products Corporation (United States)
  • Hikima Pharmaceuticals PLC (London)
  • Lunan Pharmaceutical Group Co. Ltd. (China)
  • Piramal Enterprises Limited (India)
  • Jiangsu Hengrui Medicine Co. Ltd. (China)
  • Fresenius Kabi AG (Germany)
  • AbbVie Inc. (United States)
  • Baxter International Inc. (United States)
  • Novartis AG (Switzerland)
  • Troikaa Pharmaceuticals Ltd (India)
Select User Access Type

Key Highlights of Report


Apr 2024 169 Pages 87 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Inhalation Anesthesia Quantitative research analysis
Global Inhalation Anesthesia Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck KGaA (Germany), Halocarbon Products Corporation (United States), Hikima Pharmaceuticals PLC (London), Lunan Pharmaceutical Group Co. Ltd. (China), Piramal Enterprises Limited (India), Jiangsu Hengrui Medicine Co. Ltd. (China), Fresenius Kabi AG (Germany), AbbVie Inc. (United States), Baxter International Inc. (United States), Novartis AG (Switzerland) and Troikaa Pharmaceuticals Ltd (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Adoption of Short Duration and Predictable Nature of Inhalation Anesthesia" is seen as one of major influencing trends for Inhalation Anesthesia Market during projected period 2023-2030.
The Inhalation Anesthesia market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Inhalation Anesthesia Report?

Have a Query? Click Here

Other Related Reports

Autoimmune Treatment Comprehensive Study by Type (Drugs, Diagnostic Equipment, Therapeutic and Monitoring Equipment, Other Products), Application (Childhood, Adult), Disease Type (Localized, Systemic...
$ 3750
Baby Oral Care Comprehensive Study by Type (Toothpaste, Toothbrushes, Others), Application (Consumer use, Clinics, Hospitals), Distribution Channel (Pharmacy Store, Consumer Store, Online Retail) Pla...
$ 3500
Disposable Blood Bag Comprehensive Study by End User (Blood Banks, Hospitals, Ambulatory Centers, Non-governmental Organizations (NGOs), Others), Distribution Channel (Online, Offline (Medical Stor...
$ 3650
Medical Image Management Comprehensive Study by Application (Hospitals, Diagnostic Imaging Centers, Others), Imaging Technologies (Artificial Intelligence, Augmented Reality, Three-dimensional Printi...
$ 3750
Hygiene Adhesive Comprehensive Study by Type (Woven, Non-woven), Origin (Synthetic, Natural), End Users (Kids, Adults), Product (Sanitary Napkins, Diapers, Briefs, Absorbent Underwear, Medical Produc...
$ 3750
Dietary Supplement Comprehensive Study by Type (Vitamin, Mineral, Botanical, Enzyme, Fatty Acid), Application (Energy & Weight Management, General Health, Bone & Joint Health, Gastrointestinal Health...
$ 3750